Zoonotic disease market seen reaching $65.8 billion by 2033

Persistence Market Research says the global zoonotic disease market will grow from $40.5 billion in 2026 to $65.8 billion by 2033, driven by surveillance spending, vaccine development and faster diagnostics. North America leads now, while Asia Pacific is expected to post strong growth as governments expand preparedness and healthcare infrastructure.

Why it matters: - Zoonotic disease preparedness is becoming a bigger public health and commercial priority as outbreaks spread between animals and humans. - Rising demand for vaccines, diagnostics and therapeutics is shaping spending by governments, hospitals, labs and drugmakers. - Better detection and faster response can improve outbreak control and patient outcomes.

What happened: - Persistence Market Research values the global zoonotic disease market at US$ 40.5 billion in 2026. - The market is projected to reach US$ 65.8 billion by 2033. - The forecast implies a 7.2% compound annual growth rate from 2026 to 2033. - North America holds the largest share of the market. - Asia Pacific is expected to be one of the fastest-growing regions. - The report was published July 20, 2026. - A free sample is available here. - The full report is available here. - Report customization is available here.

The details: - Vaccines and diagnostics are the leading product segments because prevention and early detection remain central to disease control. - Therapeutics remain an important part of treatment and disease management. - Hospitals account for a major share of end users because they handle complex infectious disease cases and have advanced diagnostic facilities. - Diagnostic laboratories are expanding as demand for accurate testing rises. - Research institutes support infectious disease studies and product development. - Veterinary healthcare facilities help reduce animal-to-human transmission through monitoring and vaccination programs. - Key drivers include more frequent outbreaks, rising human-animal interaction, urbanization, climate change and expanding international travel. - Governments are increasing spending on surveillance, laboratory modernization and vaccine research. - Molecular diagnostics, genomics and rapid testing are improving disease detection and treatment decisions. - High R&D costs, lengthy regulatory approvals and complex vaccine manufacturing remain major restraints. - Limited healthcare infrastructure in some developing countries restricts access to advanced diagnostics. - Regional regulatory differences and unpredictable outbreak patterns make long-term planning harder for manufacturers.

Between the lines: - The market’s growth reflects a shift from reactive outbreak response to broader prevention and surveillance systems. - Investment is moving toward tools that can shorten detection time and support faster public health decisions. - Collaboration among pharmaceutical companies, biotech firms and research institutions is becoming more important as product development gets more technical and costly. - The competitive set includes Gilead Sciences, Merck & Co., GlaxoSmithKline, Pfizer, Sanofi, Johnson & Johnson, Bharat Biotech, CureVac, Moderna, Takeda Pharmaceutical, Shionogi, Seqirus, Emergent BioSolutions, Valneva and BioNTech.

What's next: - Emerging economies are likely to attract more investment as governments build out healthcare infrastructure and surveillance systems. - Adoption of artificial intelligence, genomic sequencing, rapid diagnostics and digital health tools is expected to create new product opportunities. - Strategic partnerships are likely to speed up development across vaccines, diagnostics and therapeutics. - North America is expected to keep its lead, while Asia Pacific should continue to gain share as access and funding improve.